Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332135 | 1.00 | KIT (0.54) | KIT | |
| SCHEMBL30601489 | 0.91 | KIT (0.63) | KIT | |
| SCHEMBL26626694 | 0.91 | KIT (0.63) | KIT | |
| SCHEMBL30601476 | 0.91 | KIT (0.63) | KIT | |
| SCHEMBL26626697 | 0.91 | KIT (0.63) | KIT | |
| SCHEMBL30601441 | 0.90 | KIT (0.55) | KIT | |
| SCHEMBL31331991 | 0.90 | KIT (0.55) | KIT | |
| SCHEMBL14740384 | 0.90 | KIT (0.65) | KIT | |
| SCHEMBL30601356 | 0.90 | KIT (0.55) | KIT | |
| SCHEMBL30601454 | 0.90 | KIT (0.57) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4514799-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | claimed |
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4514799-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIT, PRKCH, PRKCB | KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.